Figure 6

Combination of eribulin and MK-2206 augments tumor suppression in a mouse xenograft STS model. (A) Representative images of subcutaneous tumors in each group are shown. (B) Tumor volumes were measured and calculated at every treatment schedule. Data are presented as the mean of data ± standard deviation (SD; n = 5). *P < 0.01. (C) Mice weights were monitored every 2 days. Data are presented as the mean of data ± SD (n = 5). Combo: combined eribulin and MK-2206.